Melinda French Gates

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease

Retrieved on: 
Mittwoch, Mai 22, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, ADAS-Cog, Patient, Mini–Mental State Examination, COYA, Therapy, LD, Safety, Blood, CMO, Biomarker, Cerebrospinal fluid, Dementia, Coya, DRS, Houston Methodist Hospital, Melinda French Gates, Pharmaceutical industry

Stanley Appel and Alireza Faridar at Houston Methodist Hospital and is funded by the Gates Foundation and the Alzheimer’s Association.

Key Points: 
  • Stanley Appel and Alireza Faridar at Houston Methodist Hospital and is funded by the Gates Foundation and the Alzheimer’s Association.
  • This controlled Phase 2 study will evaluate the safety, tolerability, and biological activity of LD IL-2 in patients with AD compared to placebo at pre-specified intervals.
  • Fred Grossman D.O., President and CMO of Coya Therapeutics, stated, “This is an important study that will help advance our expanding pipeline in dementia.
  • Overall, administration of LD IL-2 appeared to be well tolerated in the eight patients in the open-label, proof-of concept study.

Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
Donnerstag, Mai 9, 2024
PFS, FDA, SLATE, Administration, Research, HLA, Death, CRC, Doctor of Philosophy, National Cancer Institute, Vaccine, Development, IND, Melinda French Gates, NCI, AACR, Food, ESCMID, Roche, Messenger, HIV, Therapy, CEPI, Neoplasm, Infection, Gritstone bio, DNA, GMP, Clinical trial, Progression-free survival, Human services, Immunotherapy, Spark Therapeutics, MD, Disease, Patient, Acquisition, VAF, PD, COVID-19, Pharmaceutical industry

-- Gritstone to host conference call today at 4:30pm ET --

Key Points: 
  • In April 2024, Gritstone appointed Stephen Webster to its Board of Directors.
  • Mr. Webster was the Chief Financial Officer of Spark Therapeutics from July 2014 until its acquisition by Roche for $4.3 billion in December 2019.
  • Gritstone expects to share mature PFS data and additional long-term ctDNA data in the third quarter of 2024.
  • In April 2024, Gritstone presented a poster highlighting the durability and potential broad utility of its samRNA COVID-19 vaccine at ESCMID Global 2024.

NANITE AWARDED $1.8M TO DEVELOP AI-DRIVEN GENE THERAPY FOR HIV

Retrieved on: 
Mittwoch, Mai 8, 2024
Nuclear power plant, Doctor of Philosophy, Research, Success, Nanoparticle, Therapy, Bill, Melinda French Gates, HIV, Pharmaceutical industry

BOSTON, May 8, 2024 /PRNewswire/ -- Nanite, Inc. today announced a $1.8M grant from the Bill & Melinda Gates Foundation to design and optimize polymeric delivery vehicles to deliver DNA-encoded therapeutics.

Key Points: 
  • Nanite's proprietary SAYERTM platform combines AI-driven polymer design with multiplexed in vivo screening to develop best-in-class polymer nanoparticles [PNPs] for tissue-specific delivery.
  • Success would represent a significant breakthrough in HIV management, particularly in populations with limited access to medical care.
  • "One of our long-stated goals is to develop technologies that allow the benefits of gene therapy to be accessible to a wider patient population, particularly in underserved communities.
  • Nanite is dedicated to accelerating the impact of genetic medicine for the treatment of HIV."

Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact

Retrieved on: 
Montag, Mai 6, 2024
Climate change, Agriculture, Risk, Climate, Health, Infection, AMR, Partnership, Research, Vaccine, History, Disease, Attention, Science, Urinary tract infection, Poverty, Mental health, Bill, Melinda French Gates, Notifiable disease, Novo Nordisk Foundation, Immunity, Tuberculosis, Prevalence, Global health, Pharmaceutical industry

HELSINGØR, Denmark, May 6, 2024 /PRNewswire/ -- The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and innovation to advance solutions that are accessible and affordable to people in low- and middle-income countries (LMICs).

Key Points: 
  • The three-year initiative was announced at the Novo Nordisk Foundation's Global Science Summit in Denmark, where each organization committed US$100 million, for a total of US$300 million.
  • "By pooling the vast experience and unique expertise of each organization—across research, technology, innovation, and enterprise—we can make advances that wouldn't otherwise be possible," said Mads Krogsgaard Thomsen, CEO, Novo Nordisk Foundation.
  • To better protect people globally from the devastating effects of climate change on health, solutions that draw across climate, health, and agricultural science will be needed.
  • By partnering with the Novo Nordisk Foundation and the Gates Foundation, we can raise ambition, and combine resources and networks to find new ways to advance global health research—especially for those with greatest need."

Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact

Retrieved on: 
Montag, Mai 6, 2024
Climate change, Agriculture, Risk, Climate, Health, Infection, AMR, Partnership, Research, Vaccine, History, Disease, Attention, Science, Urinary tract infection, Poverty, Mental health, Bill, Melinda French Gates, Notifiable disease, Novo Nordisk Foundation, Immunity, Tuberculosis, Prevalence, Global health, Pharmaceutical industry

HELSINGØR, Denmark, May 6, 2024 /PRNewswire/ -- The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and innovation to advance solutions that are accessible and affordable to people in low- and middle-income countries (LMICs).

Key Points: 
  • The three-year initiative was announced at the Novo Nordisk Foundation's Global Science Summit in Denmark, where each organization committed US$100 million, for a total of US$300 million.
  • "By pooling the vast experience and unique expertise of each organization—across research, technology, innovation, and enterprise—we can make advances that wouldn't otherwise be possible," said Mads Krogsgaard Thomsen, CEO, Novo Nordisk Foundation.
  • To better protect people globally from the devastating effects of climate change on health, solutions that draw across climate, health, and agricultural science will be needed.
  • By partnering with the Novo Nordisk Foundation and the Gates Foundation, we can raise ambition, and combine resources and networks to find new ways to advance global health research—especially for those with greatest need."

Detect-ION announces new funding to revolutionize health diagnostics in low-income regions

Retrieved on: 
Mittwoch, Mai 1, 2024
VOC, Multimedia, Volatile organic compound, Organic compound, TB, Tuberculosis, Bill, Optimism, Melinda French Gates, Health, Congo, Hope, Democratic republic, Malaria, Medical imaging

This visionary project will leverage Detect-ION's chip-scale mass spectrometry for point-of-care breath diagnostics in LMICs, with an initial focus on detecting malaria and tuberculosis (TB) in human subjects across central Africa.

Key Points: 
  • This visionary project will leverage Detect-ION's chip-scale mass spectrometry for point-of-care breath diagnostics in LMICs, with an initial focus on detecting malaria and tuberculosis (TB) in human subjects across central Africa.
  • Through the utilization of advanced mass spectrometry techniques, the project seeks to provide affordable and timely health diagnostics, potentially saving hundreds of thousands of lives annually.
  • The project's ultimate goal is to bridge the gap in healthcare disparities and provide vital health solutions to disadvantaged communities.
  • During this 16-month project, Detect-ION will pioneer the advancement of the diagnostic capabilities of miniaturized mass spectrometry, with human trials of this groundbreaking tool being conducted in the Democratic Republic of Congo.

Gates Foundation to Establish Regional HQ in Mohammed bin Salman Non-Profit City as Part of MOU with Misk Foundation

Retrieved on: 
Montag, April 29, 2024
Education, Empowerment, Partnership, MiSK Foundation, Environment, Bill, Melinda French Gates, WEF

The strategic partnership was unveiled on the sidelines of the World Economic Forum Special Meeting in Riyadh, where it was also revealed that the Gates Foundation will establish its first regional headquarters within Mohammed Bin Salman Nonprofit City, 'Misk City', in Riyadh.

Key Points: 
  • The strategic partnership was unveiled on the sidelines of the World Economic Forum Special Meeting in Riyadh, where it was also revealed that the Gates Foundation will establish its first regional headquarters within Mohammed Bin Salman Nonprofit City, 'Misk City', in Riyadh.
  • The partnership will enhance the sharing of resources, training opportunities, and program development, substantially boosting Misk's capacity to provide significant empowerment opportunities for youth.
  • "To support the implementation of the programs announced today, the Bill & Melinda Gates Foundation will establish its first office in the region within Mohammed Bin Salman Nonprofit City.
  • Additionally, the agreement will allow the Gates Foundation to expand its geographic footprint and leverage Misk's expertise in the non-profit and youth empowerment sectors, along with the advanced infrastructure and exceptional service network of Mohammed Bin Salman Non-Profit City.

Gates Foundation to Establish Regional HQ in Mohammed bin Salman Non-Profit City as Part of MOU with Misk Foundation

Retrieved on: 
Montag, April 29, 2024
Education, Empowerment, Partnership, MiSK Foundation, Environment, Bill, Melinda French Gates, WEF

The strategic partnership was unveiled on the sidelines of the World Economic Forum Special Meeting in Riyadh, where it was also revealed that the Gates Foundation will establish its first regional headquarters within Mohammed Bin Salman Nonprofit City, 'Misk City', in Riyadh.

Key Points: 
  • The strategic partnership was unveiled on the sidelines of the World Economic Forum Special Meeting in Riyadh, where it was also revealed that the Gates Foundation will establish its first regional headquarters within Mohammed Bin Salman Nonprofit City, 'Misk City', in Riyadh.
  • The partnership will enhance the sharing of resources, training opportunities, and program development, substantially boosting Misk's capacity to provide significant empowerment opportunities for youth.
  • "To support the implementation of the programs announced today, the Bill & Melinda Gates Foundation will establish its first office in the region within Mohammed Bin Salman Nonprofit City.
  • Additionally, the agreement will allow the Gates Foundation to expand its geographic footprint and leverage Misk's expertise in the non-profit and youth empowerment sectors, along with the advanced infrastructure and exceptional service network of Mohammed Bin Salman Non-Profit City.

Owlstone Medical Secures $6.5 Million to Support Development of Breath-based Diagnostics for Infectious Disease

Retrieved on: 
Donnerstag, April 25, 2024
Biotechnology, Pharmaceutical, AIDS, Health, Medical Devices, Infectious Diseases, Philanthropy, Foundation, VOC, University, Organic compound, Atlas, University of Oxford, Volatile organic compound, Partnership, Disease, Imperial College London, Viral load, Bill, Melinda French Gates, Medicine, Infection, Diagnosis, HIV, Biomarker, TB, Tuberculosis, Medical imaging

The funding is comprised of a $5 million equity investment to advance Owlstone’s Breath Biopsy platform and $1.5 million in grant funding to develop breath-based diagnostics and identify breath biomarkers for tuberculosis (TB) and HIV.

Key Points: 
  • The funding is comprised of a $5 million equity investment to advance Owlstone’s Breath Biopsy platform and $1.5 million in grant funding to develop breath-based diagnostics and identify breath biomarkers for tuberculosis (TB) and HIV.
  • Owlstone, with support from the foundation, is interested in developing new cost-effective detection technologies for volatile organic compounds (VOCs) that could serve as markers of diseases that disproportionately affect the developing world.
  • Billy Boyle, co-founder and CEO at Owlstone Medical, said: “Early diagnosis is a critical determinant of health outcomes.
  • This investment by the Gates Foundation is testament to how Owlstone is uniquely positioned to transform infectious disease diagnosis through our Breath Biopsy platform.

Summer Health Announces Series A Fundraise from 7wireVentures and Lux Capital

Retrieved on: 
Dienstag, April 23, 2024
Well, Lux Capital, Summer, Capital, Lux, Sequoia Capital, Pediatrics, MD, Parent, Melinda French Gates, Bayer, Physician, Child, Nursing

NEW YORK, April 23, 2024 /PRNewswire/ -- Summer Health, a digital health company offering 24/7 pediatric support to parents, announced $11.65M in Series A Funding, co-led by new investor 7wire Ventures and returning investor Lux Capital.

Key Points: 
  • NEW YORK, April 23, 2024 /PRNewswire/ -- Summer Health, a digital health company offering 24/7 pediatric support to parents, announced $11.65M in Series A Funding, co-led by new investor 7wire Ventures and returning investor Lux Capital.
  • Alfred Lin of Sequoia Capital, Deena Shakir of Lux Capital, Alyssa Jaffee of 7wire Ventures, and Chelsea Clinton of Metrodora Ventures are also joining the Summer board.
  • Summer Health is a text-based companion to a family's primary pediatrician, removing the need for unnecessary visits and serving as support anytime and anywhere.
  • "Summer Health's growth is evidence that the company has tapped into a real and growing need," said Deena Shakir, general partner at Lux.